Merck & Co./$MRK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$307B
17.01
$7.28
0.30
$3.28
2.75%
Price and volume
Market cap
$307B
Beta
0.3
52-week high
$124.19
52-week low
$73.31
Average daily volume
13M
Dividend rate
$3.28
Financial strength
Total debt to equity
79.708
Interest coverage (TTM)
18.06%
Profitability
EBITDA (TTM)
28,797.332
Gross margin (TTM)
77.08%
Net profit margin (TTM)
28.08%
Operating margin (TTM)
37.69%
Effective tax rate (TTM)
13.31%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on equity (TTM)
37.17%
Valuation
Price to earnings (TTM)
17.008
Price to revenue (TTM)
4.775
Price to book
5.94
Price to tangible book (TTM)
20.6
Dividend yield (TTM)
2.65%
Forward dividend yield
2.75%
Growth
Revenue change (TTM)
1.31%
Earnings per share change (TTM)
8.01%
3-year revenue growth (CAGR)
3.12%
10-year revenue growth (CAGR)
5.11%
3-year earnings per share growth (CAGR)
8.43%
10-year earnings per share growth (CAGR)
16.65%
3-year dividend per share growth (CAGR)
5.49%
10-year dividend per share growth (CAGR)
6.05%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Merck creates separate oncology arm ahead of Keytruda patent loss
Invezz·16 hours ago
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs
Proactive Investors·17 hours ago
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.
Barrons·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $307B as of February 24, 2026.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 17.01 as of February 24, 2026.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of February 24, 2026, the dividend rate is $3.28 and the yield is 2.75%. Merck & Co. has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for April 07, 2026.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.